Advancing immune checkpoint inhibitors for cancer

Summary of current small molecular drugs targeting PD-L1 and CD47. Small molecule chemical compounds block the function of major immune checkpoint molecules by (I) competitively binding with immune checkpoint molecules to block their combination with paired receptors (BMS202, CA-170, and IMMH-010 targeting PD-L1; NCGC00138783 and 1,2,4-oxadiazole compounds targeting CD47); (II) inhibiting the level of PD-L1 and CD47 expression (e.g., fraxinellone, RRx-001, and metformin); (III) inhibiting the translation of PD-L1 (e.g., eFT508); (IV) promoting degradation of PD-L1 (e.g., HIP1R). Credit: Cancer Biology & Medicine (2024). DOI: 10.20892/j.issn.2095-3941.2024.0034 Immunotherapy has revolutionized cancer treatment, with immune checkpoint inhibitors (ICIs) playing a pivotal role. Read More